“…Analysis of clindamycin and erythromycin non-susceptibility rates over the years was performed with data from 15 studies [ 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 ], divided according to the period (until and after 2010) and locality of isolates recovery ( Table 3 ). Non-susceptibility refers to resistant and intermediate isolates, according to CLSI definitions and breakpoints.…”